{"filing":{"accession_number":"0001213900-26-096690","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304384-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026096690/ea0304384-6k_scisparc.htm"},"events":[{"id":31273,"run_id":28689,"accession_number":"0001213900-26-096690","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"SciSparc's subsidiary NeuroThera Labs announced significant enrollment progress in a clinical trial for SCI-210, an autism spectrum disorder treatment, with 26 of 60 planned children enrolled in a double-blind, randomized, placebo-controlled study at Soroka Medical Center. This represents a material operational milestone in the company's drug development program reflecting advancement toward regulatory approval and commercialization.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":34104,"accession_number":"0001213900-26-096690","item_number":"EX-99.1","item_title":"ea030438401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces significant enrollment progress in a clinical trial for SCI-210, an autism spectrum disorder treatment being developed by SciSparc's subsidiary NeuroThera Labs. The disclosure reports that 26 of 60 planned children have been enrolled in a double-blind, randomized, placebo-controlled study at Soroka Medical Center. This represents a material operational milestone in the company's drug development program, reflecting advancement toward regulatory approval and commercialization. While not a discrete event like M\u0026A or executive change, the clinical trial progress is a key operational development for a clinical-stage pharmaceutical company that would affect a reasonable investor's assessment of the registrant's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:44.523948+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31274,"run_id":28689,"accession_number":"0001213900-26-096690","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NeuroThera Labs announced its pursuit of FDA Orphan Drug Designation for SCI-110, a cannabinoid-based therapeutic for adult Tourette Syndrome, and engaged RK Strategies for government affairs support. The Orphan Drug Designation represents a material regulatory and operational milestone that could strengthen the product's market profile and advance the clinical development pathway.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":34105,"accession_number":"0001213900-26-096690","item_number":"EX-99.2","item_title":"ea030438401ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces NeuroThera's pursuit of FDA Orphan Drug Designation for SCI-110 (a cannabinoid-based therapeutic for adult Tourette Syndrome) and engagement of RK Strategies for government affairs support. This is a material operational and regulatory milestone—Orphan Drug Designation can \"potentially materially strengthen the product's market profile\" and represents a significant advancement in the clinical development pathway. While the disclosure involves regulatory strategy and clinical progress rather than a discrete financial event, M\u0026A activity, or executive change, it constitutes a material operational development affecting the registrant's drug development program and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:44.523948+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34104,"accession_number":"0001213900-26-096690","item_number":"EX-99.1","item_title":"ea030438401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces significant enrollment progress in a clinical trial for SCI-210, an autism spectrum disorder treatment being developed by SciSparc's subsidiary NeuroThera Labs. The disclosure reports that 26 of 60 planned children have been enrolled in a double-blind, randomized, placebo-controlled study at Soroka Medical Center. This represents a material operational milestone in the company's drug development program, reflecting advancement toward regulatory approval and commercialization. While not a discrete event like M\u0026A or executive change, the clinical trial progress is a key operational development for a clinical-stage pharmaceutical company that would affect a reasonable investor's assessment of the registrant's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:44.523948+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-02"},{"id":34105,"accession_number":"0001213900-26-096690","item_number":"EX-99.2","item_title":"ea030438401ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces NeuroThera's pursuit of FDA Orphan Drug Designation for SCI-110 (a cannabinoid-based therapeutic for adult Tourette Syndrome) and engagement of RK Strategies for government affairs support. This is a material operational and regulatory milestone—Orphan Drug Designation can \"potentially materially strengthen the product's market profile\" and represents a significant advancement in the clinical development pathway. While the disclosure involves regulatory strategy and clinical progress rather than a discrete financial event, M\u0026A activity, or executive change, it constitutes a material operational development affecting the registrant's drug development program and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:04:44.523948+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-02"}]}